Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aurinia Pharmaceuticals ( (AUPH) ) has shared an update.
Aurinia Pharmaceuticals said it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. The company’s management will host a webcast and conference call that morning, with a replay available on its website, offering investors and stakeholders fresh insight into Aurinia’s operational performance and pipeline development progress.
The timing of the update comes as Aurinia continues to advance its flagship lupus nephritis drug LUPKYNIS and its investigational autoimmune therapy aritinercept. The upcoming disclosure is expected to shed light on how these assets are shaping the company’s growth trajectory in the competitive autoimmune therapeutics market and may influence investor sentiment toward Aurinia’s long-term strategy.
The most recent analyst rating on (AUPH) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals’ strong financial performance and positive earnings call are the most significant factors driving the stock’s score. The company’s robust revenue growth, profitability improvements, and promising clinical developments are key strengths. However, technical indicators suggest the stock may be overbought, and its high P/E ratio indicates a premium valuation, which could limit further upside.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on therapies for autoimmune diseases with high unmet medical needs. Its key commercial product is LUPKYNIS (voclosporin), the first FDA-approved oral treatment for adult patients with active lupus nephritis, and it is also developing aritinercept, a dual BAFF and APRIL inhibitor targeting additional autoimmune indications.
Average Trading Volume: 1,107,703
Technical Sentiment Signal: Buy
Current Market Cap: $1.89B
See more data about AUPH stock on TipRanks’ Stock Analysis page.